CClinicalTrials.gg
Active, not recruitingNCT04946084AOMUpdated Jul 29, 2025

Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens

An interventional study of Tympanocentesis and Nasal Phalangeal Swab and Wash in Acute Otitis Media, sponsored by Rochester General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 6 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.

Sponsored by Rochester General Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.
  • Registered 4 months after the study started (first participant enrolled Jan 2021, registered May 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Not applicable
Ages
6 Months to 36 Months
Sex
All
01

Study summary

The investigators seek to conduct a prospective, longitudinal study to identify the dynamic changes in nasopharyngeal (NP) colonization patterns and acute otitis media (AOM) etiology involving antibiotic-resistant Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hflu).

Read the detailed description

The investigator's proposed study design involves 2 cohorts. Cohort 1: Collection of middle ear fluid(MEF), NP samples and blood at onset of AOM from otitis prone children and those who have AOM antibiotic treatment failure since these children more frequently harbor antibiotic resistant strains. Children will then be followed prospectively thereafter, collecting NP samples at pre-determined time points when the children are healthy (see cohort 2) and MEF, NP samples and blood if subsequent AOM infections occur. Cohort 2: Healthy children from whom we will prospectively collect NP samplings and blood at any of 7 pre-determined time points (age 6, 9, 12, 15, 18, 24, and/or 30-36 months old as they occur within the study time-frame) to assess commensal carriage of Spn and Hflu. MEF will be obtained from the participants at any AOM occurring, including the first and any subsequent AOM infection. Concurrently detailed demographic, vaccination, epidemiologic and risk factor data known to influence AOM epidemiology will be collected, providing scientific rigor.

Viral respiratory infections will be another focus during this project. The investigators will characterize dynamic changes in patterns of viral co-infections at onset of AOM including the common respiratory viruses RSV A, B, influenza A, B, parainfluenzae virus type 3, rhinovirus, enterovirus, human metapneumovirus, human bocavirus, adenovirus B, C and SARS-CoV-2. The studies will involve viral identification, evaluation of viral/bacterial (otopathogen) interactions and mucosal and systemic immune responses.

The investigators have identified multiple deficiencies in innate and adaptive immunity among young children who are AOM prone and introduced the term "prolonged neonatal-like immune profile (PNIP) because of striking similarities that resemble neonatal immunity. Another focus of this project will be to expand understanding of the central immune deficiencies of APM prone children using blood samples.

A a serum correlate of protection has been defined to predict the effectiveness of pneumococcal conjugate vaccines using blood samples linked to occurrence of NP colonization and AOM events in recent past work. Blood will be used to continue this work.

02

Conditions studied

  • Acute Otitis Media

Browse trials for

03

In context

Otitis Media

284 studies on the registry are indexed under Otitis Media; 33 are open to participants now.

This study's planned enrollment of 320 is above the median of 126 across 194 interventional studies indexed under Otitis Media.

Browse Otitis Media studies →

Lead sponsor

Rochester General Hospital is the lead sponsor of 11 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male or female subject age 6 to 12 months + 30 days at the time of enrollment when healthy or up to 36 months old + 30 days with an ear infection.
  • Subject has received full (3 dose) infant series of PCV.
  • Parent/legal guardian must be able and willing to bring subject to all study visits

Exclusion criteria

Exclusion Criteria:

  • Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in the study.
  • Participation in another investigational or interventional trial within the 28-day period before enrollment and during the conduct of the study. Participation in observational studies is permitted.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Other
    Healthy Children

    Samples taken from nasal swabs, nasal wash, blood draws and in the case of acute otitis media, tympanocentesis

    Procedure: Tympanocentesis · Other: Nasal Phalangeal Swab and Wash · Other: Blood Draw

Interventions

  • ProcedureTympanocentesis

    When acute otitis media is diagnosed, local anesthetic applied, small hole placed in eardrum, middle ear fluid extracted.

    Also known as: Ear Tap

  • OtherNasal Phalangeal Swab and Wash

    Nasal phalangeal swab used to retrieve sample. Nasal wash used to retrieve sample.

    Also known as: Nasal Swab, Nasal Wash

  • OtherBlood Draw

    Venipuncture

06

What researchers measure

Primary outcomes

  1. Characterize which bacterial strains in the NP

    Identify the presence of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catharralis in the nasopharynx of children using in vitro culture

    Time frame: 30 months

Secondary outcomes

  1. Characterize which bacterial strains are AOM causing pathogens

    Identify the presence of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catharralis in the nasopharynx of children using in vitro culture

    Time frame: 30 months

Other outcomes

  1. Characterize dynamic changes in patterns of viral co-infections at onset of AOM

    Identify respiratory viruses present in the nasopharynx at onset of acute otitis media in young children using polymerase chain reaction methods.

    Time frame: 30 months

  2. Determine immune responses after NP carriage and AOM infections by the common bacterial respiratory pathogens.

    Measure serum and nasopharyngeal antibody levels to common bacterial and viral respiratory pathogens with ELISA and immune cellular responses (B cells, T cells, Antigen Presenting cells using flow cytometry and ELISPOT

    Time frame: 30 Months

  3. Determine the serum antibody response that correlates with protection against NP colonization and AOM.

    Establish a correlate of protection for pneumococcal serotypes that colonize the nasopharynx and cause acute otitis media in young children using ELISA

    Time frame: 30 months

07

Study locations

1 site
  • Rochester General Hospital
    Rochester, New York 14621, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04946084
Lead sponsor
Rochester General Hospital
Responsible party
Michael Pichichero (Director, Rochester General Hospital Research Institute, Rochester General Hospital) — Principal investigator
First posted
Jun 30, 2021
Start date
Jan 1, 2021
Primary completion
Dec 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 29, 2025

Study contacts

Michael Pichichero, MD
principal investigator · Rochester General Hospital Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion